Takeda Pharmaceutical (NYSE:TAK) Releases FY 2026 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.009-3.009 for the period, compared to the consensus EPS estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $17.77 on Thursday. The firm has a market cap of $56.95 billion, a PE ratio of 45.58 and a beta of -0.07. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $18.90. The business’s fifty day simple moving average is $16.23 and its 200-day simple moving average is $17.07.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.30. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%.The firm had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.11 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts forecast that Takeda Pharmaceutical will post 1.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Finally, Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold”.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of TAK. Parkside Financial Bank & Trust lifted its stake in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Advisory Services Network LLC acquired a new stake in Takeda Pharmaceutical during the third quarter worth approximately $74,000. Finally, Kestra Advisory Services LLC acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $101,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.